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Abstract
A common haplotype on 10q26 influences the risk of age-related macular degeneration (AMD) and encompasses two
genes, LOC387715 and HTRA1. Recent data have suggested that loss of LOC387715, mediated by an insertion/deletion (in/
del) that destabilizes its message, is causally related with the disorder. Here we show that loss of LOC387715 is insufficient to
explain AMD susceptibility, since a nonsense mutation (R38X) in this gene that leads to loss of its message resides in a
protective haplotype. At the same time, the common disease haplotype tagged by the in/del and rs11200638 has an effect
on the transcriptional upregulation of the adjacent gene, HTRA1. These data implicate increased HTRA1 expression in the
pathogenesis of AMD and highlight the importance of exploring multiple functional consequences of alleles in haplotypes
that confer susceptibility to complex traits.
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Introduction
Genome-wide association studies (GWAS) have catalyzed
significant progress towards elucidating the molecular basis of
complex traits [1]. However, a substantial gap remains between
association of a trait with a genomic segment and the identification
of the causative allele(s). A locus for AMD, ARMS2 on 10q26,
illustrates this challenge.
ARMS2 is one of several regions in the genome shown by
GWAS to confer susceptibility to the disorder. However, in
contrast to the other confirmed AMD susceptibility loci CFH
(NM_000186) [2–8], C2/BF (NM_000063/NM_001710) and C3
(NM_000064) [9–11], which encompass a single gene; a region on
10q26 that contains three genes has been associated consistently
with AMD susceptibility [12–15]. Recent data have refined this
association to a haplotype that encompasses two genes,
LOC387715 (NM_001099667), a primate-specific transcript with
a proposed mitochondrial function [16] and HTRA1
(NM_002775), a multi-functional serine protease [17–18].
Initial reports describing the association between SNP
rs11200638 in the 59 end of HTRA1 and AMD focused on the
possibility that the disease-associated allele of this SNP increased
expression of HTRA1 [17–18]. However, the inability to verify
this finding in heterologous expression systems led to the
investigation of other alleles in the risk haplotype, and emphasis
was placed on LOC387715 [16]. Consistent with this possibility,
recent sequencing of the AMD-associated haplotype identified
multiple SNPs, including an in/del, that are associated with an
increased risk of AMD, and a decreased LOC387715 mRNA level
with this AMD disease haplotype [19]. To delineate the causal
genetic variations contained in the risk haplotype and to
understand their functional roles in AMD susceptibility, we
PLoS Genetics | www.plosgenetics.org 1 February 2010 | Volume 6 | Issue 2 | e1000836undertook genetic and functional investigations at the ARMS2
locus. We show that loss of LOC387715 is likely necessary but not
sufficient to explain AMD susceptibility and that a common
disease haplotype including the in/del and rs11200638 also has an
effect on the transcriptional upregulation of the adjacent gene,
HTRA1. These data, which implicate increased HTRA1 expres-
sion in the pathogenesis of AMD, suggest that the AMD risk
conferred by this region is potentially driven by multiple variants,
and highlight the importance of exploring multiple functional
consequences of alleles in haplotypes that confer susceptibility to
complex traits.
Results
Several studies have shown previously strong association of
multiple single nucleotide polymorphisms (SNPs) in chromosome
10q26 encompassing PLEKHA1, LOC387715, and HTRA1with
advanced AMD [12–24]. From our previous study [20], we
identified a common disease haplotype TAT tagged by
rs10490924, rs11200638 and rs2293870 that is significantly
associated with a risk of AMD (P=2.70610
29), as well as a
haplotype GGG that is modestly, yet significantly, associated with
protection from AMD (P=0.003). Next, to define the extent of the
haplotype structures and capture all variants in the region, we
undertook a re-sequencing effort of a region spanning ,100 kb,
starting in the 39-UTR of PLEKA and ending ,20kb downstream
of the 39 UTR of HTRA1 in six individuals with a homozygous risk
haplotype and six individuals with a homozygous protective
haplotype, followed by assessment of association of each
discovered variant with AMD in 200 AMD cases and 200 normal
controls (Table 1, Table S1, Table S2).
In agreement with recent work [19], we discovered that both
risk and protective haplotypes span 21.5kb in the ARMS2 region,
starting from upstream of LOC387715 to rs58077526, in intron 1
of HTRA1 (Figure 1, Table 1, Table S1). We confirmed recent
data [19], according to which 22 SNPs tagged a risk and a
protective haplotype including previously reported SNPs
rs10490924, rs3750848, an in/del, rs3793917, and rs11200638
(Figure 1 and Table 1). Moreover, the reported 54 base pair
insertion and 443 base pair deletion (in/del) at the 39 end of
LOC387715 resides exclusively on the disease risk haplotype that is
strongly associated with a risk of AMD (P=1.90610
226) in a Utah
Author Summary
Age-related macular degeneration (AMD) is the leading
blindness cause in western countries. Several genes
encoding components of the complement pathway—
including CFH, C2/BF,a n dC3—have been confirmed to
be associated with AMD, as well as a region on 10q26
that encompasses two genes. Recent data have sug-
gested that loss of LOC387715 on 10q26, mediated by an
insertion/deletion (in/del) at its 3’UTR that destabilizes
its message, is causally related with the disorder. We
found that a common disease haplotype including the
in/del and rs11200638 also has an effect on the
transcriptional upregulation of the adjacent gene,
HTRA1. We propose a binary model where downregula-
tion of LOC387715 and concomitant upregulation of
HTRA1 best explain the risk associated with the 10q26
AMD region.
Table 1. Association study for SNPs in 10q26 region in 200 cases and 200 controls in the Utah cohort.
SNP Chromosome Position Risk Allele Case MAF Control MAF Trend p-Value
SNP-2 (New SNP) 124198539-124198544 del 6bp 0.40 0.27 5.96610
25
rs11200630 124199674 C 0.39 0.25 8.95610
26
ENSSNP6019764 124200359 A 0.39 0.21 5.86610
26
rs10490924 124204438 T 0.41 0.23 4.90610
27
SNP-3 (New SNP) 124204546-124204547 ins GT 0.49 0.37 3.75610
25
rs36212731 124204966 T 0.30 0.20 2.47610
23
rs36212732 124205188 G 0.42 0.26 6.64610
26
rs36212733 124205201 C 0.41 0.25 4.85610
27
rs3750848 124205305 G 0.41 0.23 1.23610
26
rs3750847 124205411 T 0.35 0.24 6.43610
24
rs3750846 124205555 C 0.45 0.24 5.87610
23
SNP-4 (New SNP) 124206332-124206333 ins AT 0.69 0.61 0.02
in/del/Wt 124206811-124207253 ins 54bp, del 443bp 0.40 0.22 2.66610
27
SNP-5 (New SNP) 124207752-124207753 ins G 0.48 0.33 5.81610
25
rs3037985 124207893 del 7bp 0.68 0.59 0.03
rs3793917 124209265 G 0.40 0.22 3.22610
26
rs3763764 124210051 C 0.41 0.21 2.38610
27
rs3763764 124210051 G 0.46 0.30 4.20610
26
rs11200638 124210534 A 0.41 0.22 2.19610
27
rs1049331 124211260 T 0.43 0.29 2.68610
23
rs2293870 124211266 T, C 0.53 0.32 5.56610
27
rs58077526 or rs61871752 124220014 C 0.38 0.21 2.17610
26
doi:10.1371/journal.pgen.1000836.t001
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as well as an independent replication cohort of northern European
ancestry (442 cases, 434 controls ) (Table 2 and Table 3) and a
third replication cohort of Han Chinese in China (138 cases, 591
controls ) (Table 2 and Table 3) [19].
In contrast to the loss of function role of in/del in LOC387715,
the T allele of SNP rs2736911, a non-synonymous coding SNP
leading to a predicted premature stop (R38X) in LOC387715 is
associated with a protective haplotype T-G-Wt-G (P=4.00610
24,
Figure 2 and Table 2 and Table 4) defined by rs2736911,
rs10490924, in/del/Wt and rs11200638. We replicated these
findings twice and found that this haplotype is clearly not associated
with AMD risk; rather it is (conservatively) neutral and possibly
protective with regard to the disorder (P=0.001 in the second
replication cohort; P=0.007 in third Han Chinese cohort, Table 4).
These findings present a paradox. Recent studies have shown
the in/del to cause destabilization of LOC387715, suggesting that
loss of function at that locus might confer risk to AMD. However,
the introduction of the R38X mutation, which is also predicted to
give rise to loss of LOC387715 message due to nonsense-mediated
mRNA decay (NMD), is mildly protective. We considered two
plausible alternatives; either that effect of R38X and the in/del
have different effects on the transcript, or that loss of LOC387715
is insufficient to cause AMD. The first possibility is unlikely. Upon
quantification of LOC387715 mRNA levels in seven placentas
homozygous for the major disease haplotype, we found a 4.7-fold
reduction in endogenous LOC387715 expression (Figure 3A), in
agreement with recent published data [19]. However, we were also
able to examine LOC387715 mRNA levels in five patients
heterozygous for the R38X mutation, where we observed a 50%
Figure 1. Genes and the main SNPs in the AMD 10q26 region. The schematic diagram showing a 100 kb region subject to re-sequencing, the
AMD-associated 21.5 kb region containing 22 SNPs in the same LD block with a disease haplotype. SNPs in bold were chosen for further studies.
doi:10.1371/journal.pgen.1000836.g001
Table 2. Association of rs2736911, rs10490924, in/del/Wt, and rs11200638 in the three independent cohorts.
SNP Case-control cohort Utah cohort Hopkins cohort Han Chinese cohort
Case # vs Control # 705 vs 650 442 vs 434 138 vs 591
rs2736911 Allelic p-value 6.46610
25 1.80610
23 0.011
Heterozygote OR (95% CI) 0.611(0.475–0.788) 0.655(0.471–0.909) 0.411(0.236–0.715)
Homozygote OR (95% CI) 0.497(0.2233–1.107) 0.254(0.052–1.232) 2.48(0.410–15.031)
rs10490924 Allelic p-value 8.61610
226 4.87610
234 1.15610
213
Heterozygote OR (95% CI) 2.069(1.645–2.603) 3.175(2.333–4.321) 2.664(1.284–5.527)
Homozygote OR (95% CI) 7.191(4.518–11.444) 10.311(6.474–16.422) 8.986(4.335–18.625)
in/del/Wt Allelic p-value Freq. 1.90610
226 8.35610
234 6.03610
213
Heterozygote OR (95% CI) 2.305(1.827–2.908) 3.195(2.339–4.364) 2.395(1.189–4.825)
Homozygote OR (95% CI) 6.879(4.436–10.666) 7.998(5.255–12.173) 7.983(3.965–16.072)
rs11200638 Allelic p-value 3.64610
226 2.52610
234 5.10610
213
Heterozygote OR (95% CI) 2.413(1.922–3.031) 3.315(2.429–4.523) 4.087(1.602–10.425)
Homozygote OR (95% CI) 6.851(4.396–10.676) 10.246(6.550–16.026) 12.932(5.083–32.904)
doi:10.1371/journal.pgen.1000836.t002
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del have the same mode of action.
Given these data, we considered the potential role of HTRA1,
the only other locus encompassed by the major risk haplotype, in
the pathogenesis of AMD. We have shown previously a three-fold
increase expression of HTRA1 in the retinal pigmented epithelium
(RPE) of patients with the risk haplotype [17], while others have
also observed increased HTRA1 expression in AMD eyes in
humans [25]. In addition, a functional SNP in the promoter region
of HTRA1 is associated with increased HTRA1 expression in non-
human primates with AMD-like phenotype [26–27]. We therefore
expanded our analyses of mRNA levels in human placentas to
determine the effect of a haplotype on endogenous expression. We
found that, in addition to the observed decrease of LOC387715
message, the disease haplotype is also associated with a 2.7-fold
increase in HTRA1 expression (Figure 3B). These data confirmed
that the in/del or another component of the common risk
haplotype affects LOC387715 mRNA stability. At the same time, it
likely has an effect on HTRA1 expression. Although caution
should be exercised when translating findings from one tissue to
Table 3. Genotyping results of rs2736911, rs10490924, in/del/Wt, and rs11200638 in the three independent cohorts.
SNP Case-control cohort
Utah case-control
cohort
Hopkins case-control
cohort Han Chinese case-control cohort
Groups Case Control Case Control Case Control
Number 705 650 442 434 138 591
rs2736911 Protective Allele T Freq. 0.12 0.18 0.09 0.14 0.07 0.12
HWE 1.00 0.45 0.50 0.71 0.11 0.29
rs10490924 Risk Allele T Freq. 0.38 0.20 0.25 0.24 0.74 0.49
HWE 0.05 0.34 0.66 0.80 0.07 0.99
in/del/Wt Risk Allele in/del Freq. 0.39 0.20 0.53 0.25 0.73 0.49
HWE 0.06 0.88 0.12 0.25 0.08 1.00
rs11200638 Risk Allele A Freq. 0.41 0.22 0.53 0.25 0.77 0.52
HWE 0.38 0.22 0.10 1.00 0.05 0.28
doi:10.1371/journal.pgen.1000836.t003
Figure 2. The haplotype block in D’ of rs2736911, rs10490924, in/del/Wt, and rs11200638 in the Utah case-control cohort. The risk
haplotype C-T-in/del-A is strongly associated with advanced AMD (P=4.05610
228); the non-risk haplotype T-G-Wt-G is significantly associated with
protection of advanced AMD (P=4.00610
24). In/del and Wt refers to presence or absence of 54 base pair insertion and 443 base pair deletion, while
the letters G, T, A refer to nucleotides for the respective SNPs at rs2736911, rs10490924, and rs11200638.
doi:10.1371/journal.pgen.1000836.g002
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the effects of different haplotypes on the gene expression profiles in
the eye.
To test this hypothesis further, we generated expression
constructs that model the effect of the risk and protective
haplotype on the HTRA1 promoter using a luciferase reporter
assay on cultured human retinal pigment epithelial cells (Figure 4A
and 4B). We observed a two-fold increase in luciferase expression
in constructs that modeled the disease haplotype encompassing the
in/del and the A allele of SNP rs11200638 (MT(L+in/del),
Figure 4A and 4B). We detected no increase in luciferase
expression from constructs that contained a short disease
haplotype including the A risk allele of SNP rs11200638 but did
not contain the in/del (MT(S), Figure 4A and 4B). These findings
are consistent with Fritsche et al. and Kanda et al [16,19], who
reported an inability to verify that the A allele of SNP rs11200638
by itself alters transcriptional activity in heterologous cell systems.
We did not observe increased luciferase expression either when we
placed the in/del or A allele of SNP rs11200638 on a construct
containing a protective haplotype, suggesting that the in/del or A
allele of SNP rs11200638 by itself is insufficient to drive HTRA1
expression (WT(L+in/del), WT(L-A), Figure 4B).
Because of the potentially ambiguous nature of in vitro luciferase
assays, we repeated these experiments in an in vivo system, whereby
the constructs containing the disease haplotype including the in/
del and the protective haplotype described earlier (Figure 4A) were
electroporated into the RPE of wild-type adult mice. Luciferase
activity was assayed four days after transfection. Consistent with
Table 4. Haplotype structures generated by the Hapview program using rs2736911, rs10490924, in/del/Wt, and rs11200638.
Case-control cohort Haplotype Case Freq. Control Freq. Chi Square P Value
Utah case-control cohort C-G-Wt-G 0.450 0.590 50.455 1.22610
212
C-T-in/del-A 0.340 0.160 120.883 4.05610
228
T-G-Wt-G 0.110 0.150 12.723 4.00610
24
C-G-Wt-A 0.028 0.024 0.559 0.455
C-T-in/del-G 0.014 0.018 0.602 0.438
T-G-Wt-A 0.009 0.019 4.621 0.032
C-T-Wt-A 0.003 0.009 3.576 0.059
Hopkins case-control cohort C-G-Wt-G 0.370 0.580 76.762 1.93610
218
C-T-in/del-A 0.500 0.210 167.657 2.40610
238
T-G-Wt-G 0.076 0.120 10.773 0.001
C-G-Wt-A 0.017 0.022 0.708 0.400
C-T-Wt-G 0.010 0.021 3.752 0.053
C-G-in/del-G 0.006 0.018 5.261 0.022
T-T-in/del-A 0.014 0.007 2.085 0.149
Han Chinese case-control cohort C-G-Wt-G 0.170 0.330 27.937 1.25610
27
C-T-in/del-A 0.660 0.450 62.000 3.43610
215
T-G-Wt-G 0.037 0.084 7.376 0.007
C-G-in/del-A 0.040 0.028 0.992 0.319
C-T-Wt-G 0.023 0.032 0.620 0.431
C-G-Wt-A 0.016 0.031 1.874 0.171
C-T-Wt-A 0.015 0.028 1.502 0.220
T-T-in/del-A 0.017 0.018 0.006 0.940
C-T-in/del-G 0.009 0.014 0.482 0.488
C-G-in/del-G 0.001 0.014 3.488 0.062
doi:10.1371/journal.pgen.1000836.t004
Figure 3. Endogenous expression studies comparing effects of
genotype on HTRA1 and LOC387715. mRNA Expression levels of
LOC387715 and HTRA1 in human placenta tissues according to
haplotypes defined by SNPs rs2736911, rs10490924, in/del/Wt, and
rs11200638. Human placenta tissues from seven individuals with a
homozygous disease haplotype (C-T-in/del-A), five individuals with a
homozygous protective haplotype (C-G-Wt-G), and five individuals with
heterozygous C/T alleles at rs2736911 and homozygous protective
haplotype at rs10490924, in/del/Wt, and rs11200638 (C/T-G-Wt-G) were
harvested and analyzed. (A) In comparison to the haplotype C-G-Wt-G,
mRNA levels of LOC387715 with a homozygous disease haplotype C-T-
in/del-A and a haplotype C/T-G-Wt-G were 4.7-fold and 2.3 fold lower,
respectively. The mean 6 SD is given for each genotype. (B) mRNA
levels of HTRA1 with C-T-in/del-A was 2.7-fold higher compared to that
of C-G-Wt-G, and there was comparable expression levels between C-G-
Wt-G and C/T-G-Wt-G. The mean 6 SD is given for each genotype.
doi:10.1371/journal.pgen.1000836.g003
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luciferase activity in a construct bearing the disease haplotype
tagged by the in/del and A allele of SNP rs11200638 (P=0.032)
(Figure 4C), whereas no increased luciferase activity was observed
in a construct with the in/del on a protective haplotype
(P=0.180).
Discussion
The AMD-associated region on 10q26 poses an interesting
problem. Multiple lines of evidence support the causality of both
LOC387715 and HTRA1 in conferring risk to AMD. At the same
time, emerging data suggests that mutations in either gene alone
might be insufficient to confer such risk. The association signal is
best explained by a common disease haplotype including an in/del
in the 39 UTR of LOC387715 and the A allele of SNP rs11200638.
Although there is evidence that AMD patients exhibit loss of
LOC387715 message, the fact that haploinsufficiency in
LOC387715 alone (through the R38X mutation) does not confer
risk to AMD, suggests that either that transcript is unrelated to the
disorder, or that additional events within the risk haplotype must
occur. Although we cannot formally reject the hypothesis that loss
of LOC387715 is irrelevant to the disease, the spatiotemporal
expression pattern of this gene and its exclusive emergence with
the evolution of the macula in non-human primates, provide
partial evidence for its role in AMD pathogenesis [14,16,19,26]. At
the same time, the evidence for the involvement of HTRA1
upregulation is likewise compelling, including i) the upregulation
of the transcript in the major risk haplotype, and ii) the observed
increased HTRA1 expression in AMD eyes.
One can outline reasonable hypotheses to explain each aspect of
the discrepant data. Alternatively, a single hypothesis of dual
causality might explain all the observations. Specifically, we
speculate that concomitant downregulation of LOC387715 and
upregulation of HTRA1 can explain the disease. This theoretical
binary model is consistent with the fact that i) the common AMD-
associated haplotype affects both transcripts and ii) the protective
haplotype containing the R38X LOC387715 allele is associated
with normal HTRA1 expression (Figure 3B). Moreover, we suggest
that if changes in either gene alone were sufficient to confer AMD
susceptibility, one might have expected to discover rare alleles that
recapitulate the effect of the in/del (such as rare loss of function
mutations in LOC387715 or activating mutations in HTRA1),
neither of which have been discovered to date by us or by other
groups. The primate-specific nature of LOC387715 renders
this binary model intractable in model organisms. Nonetheless,
this model may be tested in the monkey using genetic
manipulations.
Figure 4. Heterologous Luciferase assays in vitro and in vivo. Effects of the in/del variants on HTRA1 expression in cultured human RPE cells
and mouse RPE in vivo. (A) Schematic diagram of constructs for luciferase reporter assays. The L and the S denote long and short promoter constructs,
A/G represents the allele at rs11200638, while in/del (black circle) refers to long promoter construct with an in/del. Different HTRA1 promoter
sequences corresponding to risk and wild-type alleles of in/del and rs11200638 (WT(L-A)), WT(L-G), (MT(L+in/del)), (WT(L+in/del), WT(S) and MT(S))
were placed upstream of a pGL3 reporter. (B) Luciferase activities in cultured human RPE cells transfected with different HTRA1 promoter reporter
constructs. The pGL3-Basic vector without insert (negative) was transfected into human RPE cells as a negative control. Renilla luciferase plasmid pTK-
RL was cotransfected with each construct as an internal control for normalization. Normalized luciferase activity was measured in five independent
experiments. The mean 6 SD is given for each construct. (C) Luciferase activities in mouse RPE in vivo corresponding to different HTRA1 promoter
reporter constructs. Reporter constructs were injected into the subretinal space and electroporated into mouse RPE cells. Eighteen, nineteen and
sixteen eyes were injected with WT(L), MT(L+in/del) and WT(L+in/del) constructs respectively. The firefly luciferase value was divided by the Renilla
luciferase value to give the normalized luciferase activity. This was divided by the normalized luciferase activity of empty-PGL3 and pRL-CMV to give
the relative luciferase activity ratio. Each bar represents the mean (6 SEM).
doi:10.1371/journal.pgen.1000836.g004
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Patients
This study was approved by the Institutional Review Boards of
the University of Utah, University of California San Diego, Johns
Hopkins University, and Sichuan Provincial People’s Hospital.
Subjects gave informed consent prior to participation. Participants
underwent a standard examination, which included visual acuity
measurements, dilated slit lamp biomicroscopy, and stereoscopic
color fundus photography. Grading was carried out with the
classification established by AREDS [28]. Diagnosis of advanced
AMD was based on the presence of GA or CNV (equivalent to
AREDS category 4 or 5). Control subjects were .60 years of age,
with no signs of AMD, defined as no drusen or RPE abnormalities
in the Utah collection, and controls in the Hopkins cohort and the
Chinese cohort were defined as being .60 years old, having fewer
than 5 small drusen (,63 um), and no RPE abnormalities. Patient
characteristics of the case-control series are listed in Table 5.
Genotyping
SNPs were genotyped by SNaPshot on an ABI 3100XL
analyzer (ABI, Foster City, CA, USA) according to the
manufacturer’s instructions. PCR and SNaPshot primers are
listed in Table S2. All SNPs had a genotyping success rate .98%
and accuracy .99% as judged by random re-sequencing of 20%
of samples in all three case-control series.
Re-sequencing of haplotypes
To discover all variations in the AMD susceptibility locus at
10q26, we undertook a re-sequencing of 100kb in the region
including genes PLEKHA1, LOC387715 and HTRA1. We chose
DNA samples from six individuals with a homozygous risk
haplotype and six individuals with a homozygous protective
haplotype for re-sequenbcing analysis. We designed PCR primer
pair for amplification of 1kb amplicon; each amplicon had a 50bp
overlap with next amplicons. The PCR amplicons were directly
purified using a Qiaquick kit (Qiagen, Valencia, CA, USA) and
sequenced using forward and reverse primers using the BigDye
Terminator v3.1 Cycle Sequencing Kit (ABI, Foster City, CA,
USA) according to the manufacturer’s instructions. Then the
sequencing results were annotated using the NCBI genomic DNA
sequence information (http://www.ncbi.nlm.nih.gov, build 36).
Statistical analysis
All SNP genotyping results were screened for deviations from
Hardy-Weinberg equilibrium with no SNP showing significant
deviation (p.0.05). The chi-squared test for allelic trend for an
additive model or dominant allele model over alleles was
performed with PEPI version 4.0 [29]. Odds ratios and 95%
confidence intervals were calculated by conditional logistic
regression with SPSS version 13.0. Linkage disequilibrium (LD)
structure was examined with Haploview (version 4.0) [30]. Default
settings were used, creating 95% confidence bounds on D’ to
define pair-wise SNPs in strong LD [31]. Haploview was also used
for allelic association tests.
Endogenous expression levels of HTRA1 and LOC387715
Total RNA was extracted from human placentas, and the first
strand cDNA was generated by reverse transcript using reverse
transcript kit (Invitrogen, Carlsbad, CA, USA). Real time PCR
was performed for HTRA1 mRNA qualification using ABI human
HTRA1 probe real time PCR kit (ABI, Foster city, CA, USA). RT-
PCR was performed to qualify LOC387715 mRNA levels using
primers 59-atggcagctggcttggcc-39 and 59-ttgctgcagtgtggatgatag-39
with ex taq polymerase (TaKaRa Bio USA, Mountain View, CA
USA). GAPDH was used as the internal control. Human placenta
tissues were harvested and genotyped. We measured RNA levels in
seven individuals with a homozygous disease haplotype (C-T-in/
del-A, Figure 3A and 3B), five individuals with a homozygous
protective haplotype (C-G-Wt-G, Figure 3A and 3B), and five
individuals with a homozygous non-risk haplotype with respect to
in/del/Wt and a heterozygous CT allele at rs2736911 (C/T-G-
Wt-G, Figure 3A and 3B). Significance was examined using
SPSS’s independent sample t-test.
Heterologous Luciferase assays
A 4423 bp DNA fragment containing the 21t o24423 position
from the HTRA1 translation start site including either the risk
haplotype (MT(L+in/del), Figure 4A) or protective haplotype
(WT(L-G), Figure 4A) was PCR amplified from genomic DNA of
an individual with a homozygote risk haplotype or an individual
with a protective haplotype using the following primers: forward:
cgacgcgtcggatgcagccaatcttctcctaac; reverse: agatctcgagcccggc-
gactctggcggcggcggcggtg). A DNA fragment containing 21t o
2100bp from the HTRA1 translation site including either the risk
haplotype (MT(S), Figure 4A) or protective hapotype (WT(S),
Figure 4A) was amplified from genomic DNA of an individual with
a homozygous risk haplotype or protective haplotype using the
primers, cggggtaccaactcctgggctcaaaggat and ccgctcgagtccgc-
gcctggccggggtccctcag. Constructs were subcloned into the Mlu I-
Xho I site of the pGL3-basic vector (Promega, Madison, WI,
USA). All constructs were verified by restriction enzyme digestion
and complete bidirectional DNA sequencing. The wild
type haplotype constructs carrying in/del (WT(L+in/del),
Figure 4A)was generated by subcloning of a fragment containing
in/del cutting from MT(L+in/del) using Mlu I-Nhe I. The wild
type haplotype constructs carrying A allele at rs11200638 (WT (L-
A), Figure 4A) was generated using site-directed mutagenesis kit
(Agilent Technologies, La Jolla, CA). A positive control plasmid
(pGL3-control Vector) containing an SV40 enhancer and
Table 5. Disease status, gender, and age of subjects in the study.
Case-control cohort Utah case-control cohort Hopkins case-control cohort Han Chinese case-control cohort
GA CNV Controls GA CNV Controls CNV Controls
232 473 650 141 301 434 138 591
Sex-Number (%) Female 139 (60) 243 (50) 400 (62) 80 (57) 163 (54) 228 (53) 66 (48) 272 (46)
Male 93 (40) 230 (50) 250 (38) 61 (43) 138 (46) 206 (47) 72 (52) 319 (54)
Average Age-years 84.09 82.85 75.30 82.51 79.51 78.10 68.10 66.50
doi:10.1371/journal.pgen.1000836.t005
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(Madison, WI, USA).
Human RPE cells were split into 24-well plates and cotrans-
fected 24 hours later with 1ng of the transfection control Renilla
luciferase plasmid pTK-RL (Promega, Madison, WI) and 200ng of
one of the following plasmids: pGL3-basic, pGL3-control, WT(L-
A), WT(L-G), WT(L+in/del), MT(L+in/del), WT(S) and MT(S).
Transfections (n=6, three preps for each construct and 2
transfections for each preps) were done using the Fugene-6
protocol according to manufacturer’s specifications (Roche
Applied Science, Mannheim, Germany). Forty-eight hours after
transfection, cells were washed with PBS twice and luciferase
activities measured with the Dual-Luciferase Assay Kit (Promega,
Madison, WI). Fold induction was derived relative to normalized
reporter activity.
In vivo transfection by electroporation
In vivo transfection was done by subretinal injection of reporter
plasmids followed by electroporation as described [32]. Briefly,
C57BL/6 mice (4–5 weeks old) were given a subretinal injection of
1ml of PBS containing 0.5 ug of pGL3 containing one of the firefly
luciferase constructs described above and 0.25 ng of Renilla
luciferase plasmid ( pRL-CMV, Promega, Madison, WI) for
normalization. After injection, two steel electrodes separated by
about 3.0 mm were placed on the posterior sclera and an
ECM830 electroporator (BTX, San Diego, CA, USA) was used
to deliver eight 50 ms electric pulses separated by 100 ms with
voltage set at 30V. The eyes were enucleated 65–68h after
electroporation and the cornea and lens were removed. Posterior
eyecups were minced and homogenized in 100 ml of Reporter
Lysis Buffer (Promega, Madison, WI). Firefly and Renilla
luciferase activities were measured using 40ml of lysate and a
Dual-Luciferase Reporter Assay System (Promega, Madison, WI).
The firefly luciferase value was divided by the Renilla luciferase
value to give the normalized luciferase activity. The normalized
luciferase activity of each test plasmid injection group was divided
by the normalized luciferase activity of empty-PGL3 and pRL-
CMV injection group to give the relative luciferase activity ratio.
Statistical analysis was done using ANOVA and Bonferroni/Dunn
test.
Supporting Information
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